Top 3 drug approvals in oncology: May 2021

Written by Jade Parker, Senior Editor
Clinical trials Drug approvals For clinicians Industry and business News
OC Monthly Drug Approvals TW

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Keytruda® (pembrolizumab) Approved: 5 May 2021 Company: Merck & Co. (NJ, USA) Indication: Unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma The first big approval in May was yet again for pembrolizumab. The US FDA approved the drug, in combination with trastuzumab and chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The approval is a welcome piece of good news for...

To view this content, please register now for access

It's completely free